In silico pharmacogenetics of warfarin metabolism

Pharmacogenetics of Warfarin

วารสารโลหติวทิยาและเวชศาสตร บรกิารโลหติ ป ที ่ 16 ฉบบัที ่ 3 กรกฎาคม-กนัยายน 2549 Warfarin is the mainstay of anticoagulation therapy. It is used for the prevention and treatment of venous thromboembolism, myocardial infarction, and strokes.1 Its clinical use, however, is complicated by the fact that it has a narrow therapeutic index with associated adverse effects that are potentially serious,...

Warfarin pharmacogenetics meets clinical use.

ence is sufficient to disrupt the nucleolar structure.9 Similarly, the anticancer peptide CIGB-300 leads to nucleolar disassembly and apoptosis, most likely through its capability to bind NPM1.10 Because AML cells carrying the NPM1 mutation are depleted of wild-type NPM1 protein in their nucleolar pool (because of haploinsufficiency and cytoplasmic dislocation through formation of heterodimers ...

Warfarin: a case history in pharmacogenetics.

Both hereditary and environmental factors contribute to inter-individual variability in drug response. The considerable interest in the role of genes has to be balanced with the contribution of external influences. Warfarin provides a useful case study of the need to integrate both genetic and non-genetic information when selecting the right dose for a patient. This article discusses the latest...

Use of Pharmacogenetics in Guiding Treatment with Warfarin

Warfarin is the most widely used oral anticoagulant for the treatment of thromboembolic disorders and for stroke prophylaxis. Warfarin is a problematic drug because it exhibits large interindividual variation in the required therapeutic dose, has a narrow therapeutic range, and shows multiple food and drug interactions. Its anticoagulant effect is monitored by measuring the international normal...

Warfarin Pharmacogenetics: A Rising Tide for its Clinical Value Running title: Johnson, Clinical utility of warfarin pharmacogenetics